Cargando…

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

BACKGROUND: G6PD enzyme deficiency is a common enzymatic X-linked disorder. Deficiency of the G6PD enzyme can cause free radical-mediated oxidative damage to red blood cells, leading to premature haemolysis. Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Eugenia, Zhong, Daibin, Raya, Beka, Pestana, Kareen, Koepfli, Cristian, Lee, Ming-Chieh, Yewhalaw, Delenasaw, Yan, Guiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781416/
https://www.ncbi.nlm.nih.gov/pubmed/31590661
http://dx.doi.org/10.1186/s12936-019-2981-x
_version_ 1783457367930699776
author Lo, Eugenia
Zhong, Daibin
Raya, Beka
Pestana, Kareen
Koepfli, Cristian
Lee, Ming-Chieh
Yewhalaw, Delenasaw
Yan, Guiyun
author_facet Lo, Eugenia
Zhong, Daibin
Raya, Beka
Pestana, Kareen
Koepfli, Cristian
Lee, Ming-Chieh
Yewhalaw, Delenasaw
Yan, Guiyun
author_sort Lo, Eugenia
collection PubMed
description BACKGROUND: G6PD enzyme deficiency is a common enzymatic X-linked disorder. Deficiency of the G6PD enzyme can cause free radical-mediated oxidative damage to red blood cells, leading to premature haemolysis. Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD deficient people. In this study, the prevalence and distribution of G6PD mutations were investigated across broad areas of Ethiopia, and tested the association between G6PD genotype and phenotype with the goal to provide additional information relevant to the use of primaquine in malaria treatment. METHODS: This study examined G6PD mutations in exons 3–11 for 344 febrile patient samples collected from seven sites across Ethiopia. In addition, the G6PD enzyme level of 400 febrile patient samples from Southwestern Ethiopia was determined by the CareStart™ biosensor. The association between G6PD phenotype and genotype was examined by Fisher exact test on a subset of 184 samples. RESULTS: Mutations were observed at three positions of the G6PD gene. The most common G6PD mutation across all sites was A376G, which was detected in 21 of 344 (6.1%) febrile patients. Thirteen of them were homozygous and eight were heterozygous for this mutation. The G267+119C/T mutation was found in 4 (1.2%) individuals in South Ethiopia, but absent in other sites. The G1116A mutation was also found in 4 (1.2%) individuals from East and South Ethiopia. For the 400 samples in the south, 17 (4.25%) were shown to be G6PD-deficient. G6PD enzyme level was not significantly different by age or gender. Among a subset of 202 febrile patients who were diagnosed with malaria, 11 (5.45%) were G6PD-deficient. These 11 infected samples were diagnosed with Plasmodium vivax by microscopy. Parasitaemia was not significantly different between the G6PD-deficient and G6PD-normal infections. CONCLUSIONS: The prevalence of G6PD deficiency is modest among febrile patients in Ethiopia. G6PD deficiency testing is thus recommended before administrating primaquine for radical cure of P. vivax infected patients. The present study did not indicate a significant association between G6PD gene mutations and enzyme levels.
format Online
Article
Text
id pubmed-6781416
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67814162019-10-17 Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia Lo, Eugenia Zhong, Daibin Raya, Beka Pestana, Kareen Koepfli, Cristian Lee, Ming-Chieh Yewhalaw, Delenasaw Yan, Guiyun Malar J Research BACKGROUND: G6PD enzyme deficiency is a common enzymatic X-linked disorder. Deficiency of the G6PD enzyme can cause free radical-mediated oxidative damage to red blood cells, leading to premature haemolysis. Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD deficient people. In this study, the prevalence and distribution of G6PD mutations were investigated across broad areas of Ethiopia, and tested the association between G6PD genotype and phenotype with the goal to provide additional information relevant to the use of primaquine in malaria treatment. METHODS: This study examined G6PD mutations in exons 3–11 for 344 febrile patient samples collected from seven sites across Ethiopia. In addition, the G6PD enzyme level of 400 febrile patient samples from Southwestern Ethiopia was determined by the CareStart™ biosensor. The association between G6PD phenotype and genotype was examined by Fisher exact test on a subset of 184 samples. RESULTS: Mutations were observed at three positions of the G6PD gene. The most common G6PD mutation across all sites was A376G, which was detected in 21 of 344 (6.1%) febrile patients. Thirteen of them were homozygous and eight were heterozygous for this mutation. The G267+119C/T mutation was found in 4 (1.2%) individuals in South Ethiopia, but absent in other sites. The G1116A mutation was also found in 4 (1.2%) individuals from East and South Ethiopia. For the 400 samples in the south, 17 (4.25%) were shown to be G6PD-deficient. G6PD enzyme level was not significantly different by age or gender. Among a subset of 202 febrile patients who were diagnosed with malaria, 11 (5.45%) were G6PD-deficient. These 11 infected samples were diagnosed with Plasmodium vivax by microscopy. Parasitaemia was not significantly different between the G6PD-deficient and G6PD-normal infections. CONCLUSIONS: The prevalence of G6PD deficiency is modest among febrile patients in Ethiopia. G6PD deficiency testing is thus recommended before administrating primaquine for radical cure of P. vivax infected patients. The present study did not indicate a significant association between G6PD gene mutations and enzyme levels. BioMed Central 2019-10-07 /pmc/articles/PMC6781416/ /pubmed/31590661 http://dx.doi.org/10.1186/s12936-019-2981-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Lo, Eugenia
Zhong, Daibin
Raya, Beka
Pestana, Kareen
Koepfli, Cristian
Lee, Ming-Chieh
Yewhalaw, Delenasaw
Yan, Guiyun
Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia
title Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia
title_full Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia
title_fullStr Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia
title_full_unstemmed Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia
title_short Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia
title_sort prevalence and distribution of g6pd deficiency: implication for the use of primaquine in malaria treatment in ethiopia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781416/
https://www.ncbi.nlm.nih.gov/pubmed/31590661
http://dx.doi.org/10.1186/s12936-019-2981-x
work_keys_str_mv AT loeugenia prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT zhongdaibin prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT rayabeka prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT pestanakareen prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT koepflicristian prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT leemingchieh prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT yewhalawdelenasaw prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia
AT yanguiyun prevalenceanddistributionofg6pddeficiencyimplicationfortheuseofprimaquineinmalariatreatmentinethiopia